Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity
Angkana T. Huang, Bernardo García‐Carreras, Matt D. T. Hitchings, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 924

Showing 1-25 of 924 citing articles:

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Alba Grifoni, Daniela Weiskopf, Sydney I. Ramirez, et al.
Cell (2020) Vol. 181, Iss. 7, pp. 1489-1501.e15
Open Access | Times Cited: 3759
A serological assay to detect SARS-CoV-2 seroconversion in humans
Fatima Amanat, Daniel Stadlbauer, Shirin Strohmeier, et al.
Nature Medicine (2020) Vol. 26, Iss. 7, pp. 1033-1036
Open Access | Times Cited: 1877
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
Marina Pollán, Beatriz Pérez‐Gómez, Roberto Pastor‐Barriuso, et al.
The Lancet (2020) Vol. 396, Iss. 10250, pp. 535-544
Open Access | Times Cited: 1805
Immunology of COVID-19: Current State of the Science
Nicolas Vabret, Graham J. Britton, Conor Gruber, et al.
Immunity (2020) Vol. 52, Iss. 6, pp. 910-941
Open Access | Times Cited: 1654
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang, Gang Zeng, Hongxing Pan, et al.
The Lancet Infectious Diseases (2020) Vol. 21, Iss. 2, pp. 181-192
Open Access | Times Cited: 1428
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Ania Wajnberg, Fatima Amanat, Adolfo Firpo, et al.
Science (2020) Vol. 370, Iss. 6521, pp. 1227-1230
Open Access | Times Cited: 1186
Age-specific mortality and immunity patterns of SARS-CoV-2
Megan O’Driscoll, Gabriel Ribeiro dos Santos, Lin Wang, et al.
Nature (2020) Vol. 590, Iss. 7844, pp. 140-145
Open Access | Times Cited: 1155
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
John S. Tregoning, Katie E. Flight, Sophie L. Higham, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 10, pp. 626-636
Open Access | Times Cited: 1031
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Kevin W. Ng, Nikhil Faulkner, Georgina H. Cornish, et al.
Science (2020) Vol. 370, Iss. 6522, pp. 1339-1343
Open Access | Times Cited: 896
Genomic evidence for reinfection with SARS-CoV-2: a case study
Richard Tillett, Joel Sevinsky, Paul D. Hartley, et al.
The Lancet Infectious Diseases (2020) Vol. 21, Iss. 1, pp. 52-58
Open Access | Times Cited: 805
Household Transmission of SARS-CoV-2
Zachary J. Madewell, Yang Yang, Ira M. Longini, et al.
JAMA Network Open (2020) Vol. 3, Iss. 12, pp. e2031756-e2031756
Open Access | Times Cited: 688
Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
Luis F. García
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 657
Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients
Anita Iyer, Forrest K. Jones, Ariana Nodoushani, et al.
Science Immunology (2020) Vol. 5, Iss. 52
Open Access | Times Cited: 653
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
Victoria Hall, Sarah Foulkes, André Charlett, et al.
The Lancet (2021) Vol. 397, Iss. 10283, pp. 1459-1469
Open Access | Times Cited: 649
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
Christian Holm Hansen, Daniela Michlmayr, Sophie Gubbels, et al.
The Lancet (2021) Vol. 397, Iss. 10280, pp. 1204-1212
Open Access | Times Cited: 642
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Manish Sadarangani, Arnaud Marchant, Tobias R. Kollmann
Nature reviews. Immunology (2021) Vol. 21, Iss. 8, pp. 475-484
Open Access | Times Cited: 530
Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections
Petra Zimmermann, Nigel Curtis
Archives of Disease in Childhood (2020) Vol. 106, Iss. 5, pp. 429-439
Open Access | Times Cited: 496
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
Stuart P. Weisberg, Thomas J. Connors, Yun Zhu, et al.
Nature Immunology (2020) Vol. 22, Iss. 1, pp. 25-31
Open Access | Times Cited: 488
Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital
Alberto L. García‐Basteiro, Gemma Moncunill, Marta Tortajada, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 412
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis
Ali Rostami, Mahdi Sepidarkish, Mariska Leeflang, et al.
Clinical Microbiology and Infection (2020) Vol. 27, Iss. 3, pp. 331-340
Open Access | Times Cited: 383
Diagnostics for COVID-19: moving from pandemic response to control
Rosanna W. Peeling, Dominique Heymann, Yik-Ying Teo, et al.
The Lancet (2021) Vol. 399, Iss. 10326, pp. 757-768
Open Access | Times Cited: 381
Immunological characteristics govern the transition of COVID-19 to endemicity
Jennie S. Lavine, Ottar N. Bjørnstad, Rustom Antia
Science (2021) Vol. 371, Iss. 6530, pp. 741-745
Open Access | Times Cited: 380
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
Wan Ni Chia, Feng Zhu, Sean Wei Xiang Ong, et al.
The Lancet Microbe (2021) Vol. 2, Iss. 6, pp. e240-e249
Open Access | Times Cited: 380
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
Elizabeth M. Anderson, Eileen C. Goodwin, Anurag Verma, et al.
Cell (2021) Vol. 184, Iss. 7, pp. 1858-1864.e10
Open Access | Times Cited: 374
Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions
Sheikh Taslim Ali, Lin Wang, Eric H. Y. Lau, et al.
Science (2020) Vol. 369, Iss. 6507, pp. 1106-1109
Open Access | Times Cited: 362
Page 1 - Next Page

Scroll to top